ImageneBio, Inc. (NASDAQ:IMA) Receives Average Rating of “Hold” from Analysts

Shares of ImageneBio, Inc. (NASDAQ:IMA) have been given an average rating of “Hold” by the five research firms that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has issued a hold recommendation, one has assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $26.50.

Several research analysts have issued reports on the company. Zacks Research downgraded ImageneBio from a “strong-buy” rating to a “hold” rating in a report on Monday, September 29th. Leerink Partnrs upgraded ImageneBio to a “strong-buy” rating in a report on Friday, October 24th. Leerink Partners initiated coverage on ImageneBio in a report on Friday, October 24th. They set an “outperform” rating and a $30.00 price objective for the company. Wedbush lowered shares of ImageneBio from a “neutral” rating to an “underperform” rating in a research note on Tuesday, November 25th. Finally, Wall Street Zen cut shares of ImageneBio from a “hold” rating to a “strong sell” rating in a research report on Saturday, November 15th.

ImageneBio Trading Up 0.5%

IMA opened at $6.50 on Friday. ImageneBio has a 1-year low of $6.19 and a 1-year high of $23.28. The stock has a market capitalization of $72.67 million, a PE ratio of -0.81 and a beta of 0.44. The firm has a 50-day moving average price of $7.61 and a two-hundred day moving average price of $11.68.

ImageneBio (NASDAQ:IMA) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($2.91) EPS for the quarter, missing the consensus estimate of ($1.47) by ($1.44). On average, research analysts predict that ImageneBio will post -0.91 EPS for the current year.

Institutional Investors Weigh In On ImageneBio

Institutional investors have recently made changes to their positions in the stock. Deep Track Capital LP acquired a new position in ImageneBio in the third quarter valued at about $7,160,000. Blue Owl Capital Holdings LP bought a new stake in shares of ImageneBio in the 3rd quarter valued at about $4,409,000. Atlas Venture Life Science Advisors LLC bought a new stake in shares of ImageneBio in the 3rd quarter valued at about $3,079,000. Aldebaran Capital LLC acquired a new stake in shares of ImageneBio in the 1st quarter valued at approximately $317,000. Finally, Vanguard Group Inc. bought a new position in ImageneBio during the 3rd quarter worth approximately $1,902,000. 75.00% of the stock is owned by institutional investors and hedge funds.

About ImageneBio

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025.